CRISPR Therapeutics AG Balance Sheet
CRSP / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
CRISPR Therapeutics AG had $2.3B in total assets and $1.9B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M | $1.2B | $943.8M | $456.6M | $239.8M | $315.5M | $156.0M | $945.0K |
| Accounts Receivable | $0 | $25.0M | $200.0M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $2.6M | $3.2M | $339.0K | - |
| Current Assets | $2.0B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $987.5M | $466.4M | $248.4M | $320.2M | $156.8M | - |
| PP&E (Net) | $115.9M | $134.1M | $151.9M | $163.6M | $137.6M | $42.2M | $31.3M | $18.5M | $18.9M | $21.0M | $1.3M | - |
| Total Assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B | $1.8B | $1.1B | $489.0M | $271.3M | $345.0M | $159.4M | - |
| Current Liabilities | $149.1M | $87.8M | $108.8M | $121.1M | $119.9M | $94.3M | $57.1M | $27.7M | $14.5M | $22.0M | $10.2M | - |
| Shareholders' Equity | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $939.4M | $392.2M | $187.8M | $232.8M | -$29.1M | -$7.0M |